Fifth Generation Cephalosporins and Their Value in Treating cSSTIs

Speciality: Infectious diseases


Speaker:

Dr. Atul Mishra | Professor of General Surgery, DMC & H

Dr. Neha Gupta | Senior Infectious Diseases Physician

Description:

A warm welcome to all the medical professionals in this interesting session of use of fifth generation cephalosporins in treating complicated skin and soft tissue infections (cSSTIs). In this webinar, the speakers, Dr. Atul Mishra and Dr. Neha Gupta has shared the important facts associated with the management of cSSTIs. 

Antibiotic resistance is the most common threat that the infectious diseases specialists need to deal with. The emergence of different multi antibiotic resistant infectious strains are threatening the treatment approaches. 

Complicated skin and soft tissue infections (cSSTIs) typically involve deep soft tissues. It is mostly observed in patients with underlying disease and it often requires intravenous antibiotic therapy, surgical intervention, or both. The situation of cSSTIs becomes worse when it is accompanied by MRSA infection.

Fifth generation cephalosporin, Ceftobiprole. possesses anti-pseudomonal activity and appears to be less susceptible to development of resistance. Further, it can also treat infections that are resistant to other antibiotics, including MRSA infections.

Therefore, have an overall knowledge on cSSTIs  management using fifth generation cephalosporin from different case presentations. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars

See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

2.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

3.

Survival improved with lobectomy, segmentectomy in early non-small cell lung cancer

4.

Prostate cancer 'is not a death knell': Early detection and personalized care improve outcomes, study shows

5.

Two medications might work better for breast cancers that are resistant to one.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot